DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Semaglutide 2.4 mg (Wegovy). Adults with established CV disease and overweight or obesity, without diabetes.
First MACE (CV death, non-fatal MI, non-fatal stroke).
20% relative risk reduction in MACE (HR 0.80, 95% CI 0.72-0.90). First weight-loss drug with established CV benefit in non-diabetic population.
Adults with established CV disease and overweight or obesity, without diabetes.
Once-weekly subcutaneous semaglutide 2.4 mg vs placebo.
First MACE (CV death, non-fatal MI, non-fatal stroke).
20% relative risk reduction in MACE (HR 0.80, 95% CI 0.72-0.90). First weight-loss drug with established CV benefit in non-diabetic population.
Lincoff AM et al, NEJM 2023;389:2221-2232